The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in Diabetes
暂无分享,去创建一个
[1] R. D. de Boer,et al. Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[2] M. Nauck,et al. Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function? , 2010, Diabetes.
[3] A. Peters. Incretin-based therapies: review of current clinical trial data. , 2010, The American journal of medicine.
[4] S. Mudaliar,et al. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. , 2010, The American journal of medicine.
[5] P. Dandona,et al. Insulin as an anti-inflammatory and antiatherogenic modulator. , 2009, Journal of the American College of Cardiology.
[6] J. Holst,et al. Four weeks of near‐normalization of blood glucose has no effect on postprandial GLP‐1 and GIP secretion, but augments pancreatic B‐cell responsiveness to a meal in patients with Type 2 diabetes , 2008, Diabetic medicine : a journal of the British Diabetic Association.
[7] Mark Ellrichmann,et al. Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance , 2008, Diabetes.
[8] J. McGill,et al. The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitus. , 2005, Journal of the American College of Cardiology.
[9] A. Ceriello. Postprandial hyperglycemia and diabetes complications: is it time to treat? , 2005, Diabetes.
[10] J. Holst,et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. , 2004, American journal of physiology. Endocrinology and metabolism.
[11] M. Quon,et al. Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile. , 2004, American journal of physiology. Heart and circulatory physiology.
[12] E. Bonora,et al. Insulin Causes Endothelial Dysfunction in Humans: Sites and Mechanisms , 2002, Circulation.
[13] E. Benjamin,et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. , 2002, Journal of the American College of Cardiology.
[14] A. Ceriello,et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress , 2001, Diabetologia.
[15] D. Drucker,et al. Minireview: the glucagon-like peptides. , 2001, Endocrinology.
[16] K. Kugiyama,et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. , 1999, Journal of the American College of Cardiology.
[17] R. Ross. The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.
[18] J. Holst,et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.
[19] D. B. Zilversmit. Atherogenesis: a postprandial phenomenon. , 1979, Circulation.
[20] R. DeFronzo,et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.